Measuring the serum progesterone level on the day of transfer can be an additional tool to maximize ongoing pregnancies in single euploid frozen blastocyst transfers

Fazilet Kubra Boynukalin, Meral Gultomruk, Emre Turgut, Berfu Demir, Necati Findikli, Munevver Serdarogullari, Onder Coban, Zalihe Yarkiner and Mustafa Bahceci

Abstract

Background: Endometrial preparation with hormone replacement therapy (HRT) is the preferred regimen for clinicians due to the opportunity to schedule the day of embryo transfer and for patients due to the requirement of fewer visits for frozen-warmed embryo transfers (FET). The increasing number of FETs raises the question of the serum P levels required to optimize the pregnancy outcome on the embryo transfer day.

Methods: This prospective cohort study includes patients who underwent single euploid FET. All patients received HRT with oestradiol valerate (EV) and 100 mg of intramuscular (IM) progesterone (P). FET was scheduled 117–120 h after the first IM administration of 100 mg P. The serum P level was analyzed 1 h before the embryo transfer (ET). In all cycles, only embryos that were biopsied on day 5 were utilized for FET. Next generation sequencing (NGS) was used for comprehensive chromosomal analysis.

Results: Overall, the ongoing pregnancy rate (OPR) was 58.9% (99/168). Data were then categorized according to the presence (Group I; n = 99) or the absence (Group II; n = 69) of an ongoing pregnancy. No significant differences regarding, female age, body mass index (BMI), number of previous miscarriages, number of previous live births, sperm concentration, number of oocytes retrieved, number of mature oocytes (MII), rate of fertilized oocytes with two pronuclei (2PN), trophectoderm score, inner cell mass (ICM) score, endometrial thickness (mm), oestradiol (E2) and P levels prior to IM P administration were found between two groups. The P levels on the day of ET (ng/ml) were significantly higher in Group I (28 (5.6–76.4) vs 16.4 (7.4–60) p = 0.039). The P level on the day of ET was a predictor of a higher OPR (p < 0.001 OR: 1.033 95%CI [1.009–1.056]) after multivariate analysis. The ROC curve showed a significant predictive value of serum P levels on the day of ET for OPR, with an AUC (95%CI) = 0.716 (0.637–0.795). The optimal cut-off value for prediction of the OPR was a P level of 20.6 ng/ml (71.7% sensitivity, 56.5% specificity).

Conclusions: The present study suggests a minimum threshold of the serum P value on the day of ET that needs to be reached in HRT cycles to optimize the clinical outcome. Individualization of the P dosage should be evaluated in further studies.

Keywords: Serum progesterone, Frozen-warmed embryo transfer, Pregnancy, Euploidy, Embryo biopsy
Introduction
The number of frozen-warmed embryo transfer (FET) procedures has been increasing worldwide in the last decade. The main reasons underlying this circumstance are improvements in controlled ovarian hyperstimulation (COH) regimens, higher embryo survival rates after the implementation of vitrification in the laboratory and elective single embryo transfer (ET) policies. Freeze-all policies for the prevention of ovarian hyperstimulation syndrome and detrimental aspects of ovarian stimulation such as supraphysiologic oestradiol (E$_2$) levels and premature progesterone (P) elevation are factors that increase FET cycles. The best endometrial preparation protocol is still the subject of an ongoing debate [1–3]; however, hormone replacement therapy (HRT) is a more popular regimen owing to the opportunity to schedule the day of embryo transfer and its reduced monitoring requirements [4]. The best administration route of oestradiol and P, the ideal dosage and duration, and the length of exposure to P before ET have not been well defined.

The increasing number of FET procedures raises the question of the serum P level that is required to optimize the pregnancy outcome because defining an optimal level may allow the individualization of FET in HRT. There is paucity of data on this topic, and most existing data are based on vaginal P administration [5–9]. A similar controversy is ongoing with respect to the intramuscular (IM) route. Data from two separate studies revealed lower pregnancy rates with low [10] and high [11] serum P levels on the day of ET. Recently, one prospective study on oocyte recipients [8] and one retrospective study conducted on euploid FET [7] showed a significant detrimental effect of a low serum P level on the day or the day before ET on pregnancy outcomes in patients receiving vaginal P administration. However, an optimal range on the day of ET was reported in a retrospective analysis [9].

Our aim in this prospective study is to determine whether an optimal P level exists for patients receiving IM administration on the day of FET for a successful outcome in cycles utilizing single euploid blastocysts.

Materials and methods
Design and setting
This prospective cohort study was performed at the Bahceci Health Group in Istanbul, Turkey, between March 1 and August 31, 2018. This study was approved by the Institutional Review Board with a reference number of 40. During this period, 328 euploid frozen-warmed blastocyst transfers were performed.

Patient population
Between March 1 and August 31, 2018, 972 patients started endometrial preparation for FET were assessed for eligibility (Fig. 1). One hundred sixty-eight FET cycles utilizing euploid blastocyst were included. In all cycles, the embryos were artificially hatched on day 3 and biopsied on day 5 as hatching blastocysts. Only day 5 hatching blastocysts which are fully (100%) survived after warming procedure were included in this study. All patients underwent endometrial preparation with HRT. Patients with uterine diseases (e.g., fibroids, polyps, and previously diagnosed Müllerian abnormalities), the presence of hydrosalpinx or an endometrial thickness <7 mm after HRT and embryos biopsied on day 6 were excluded.

In all cycles, COH, oocyte retrieval, denudation, intracytoplasmic sperm injection (ICSI), embryo culture, vitrification, and warming procedures were performed as described in detail previously by Serdarogullari and colleagues [12]. Moreover, embryo grading, trophectoderm biopsy, and embryo transfer were performed in accordance with standard operating procedures, as described below.

Embryo morphology assessment and trophectoderm biopsy
The developmental characteristics of each individual embryo were recorded. The blastocyst morphology evaluation was performed at 114 h after ICSI according to the classification of Gardner and Schoolcraft [13].

Assisted hatching (AH) was applied to each embryo by creating a hole of approximately 20 μm using a laser pulse (OCTAX NaviLase, MTG, Germany) on day 3 of embryo development. After laser application on day 3, the embryos were transferred to fresh medium until the day of biopsy. Biopsy of each embryo was performed in 5 μl droplets of mHTF with Gentamicin (mHTF, Irvine Scientific, CA, USA) containing 10% SSS (Irvine Scientific, CA, USA). A trophectoderm biopsy was performed by the pulling method. On average, between five and eight cells were removed from the trophectoderm, and the extracted cells were placed in polymerase chain reaction tubes, and kept frozen at −20°C until PGT-A.

Evaluation of viability after warming and extended culture
After the warming procedure was completed, the embryos were transferred to an equilibrated culture dish to assess the cryo-survival rate. Blastocyst grading was performed 2–3 h after the warming procedure. Viability after warming was quantified and classified based on the percentage of intact blastomeres (100%, ≥50, <50, 0%) that were present in a blastocyst stage embryo and the blastocele re-expansion.
Endometrial preparation and support
Endometrial preparation for FET involved HRT. Briefly, each woman was administered oral oestradiol (Estrofem, Novo Nordisk, Istanbul, Turkey) in a step-up regimen (4 mg/day on days 1–4, 6 mg/day on days 5–8, and 8 mg/day on days 9–12). Transvaginal ultrasonography (TV-USG) (GE Ultrasound Korea Ltd., Korea, Model; Voluson S6) was performed on day 13 to measure endometrial thickness, and the cycle was cancelled if the endometrial thickness was < 7 mm. The serum P level was also measured, and the embryo transfer was cancelled if this concentration was > 1 ng/ml. Oral oestradiol supplementation was continued at 8 mg/day, and IM administration of 100 mg of P (Progestan, Koçak Farma, Turkey) was started. Embryo transfer was performed on the 6th day of progesterone administration. Oral oestradiol was continued until the 7th week, and IM P administration was continued until the 10th week of pregnancy.

Serum analysis and hormone measurement
Blood samples were obtained to determine serum P on the sixth day of P administration, one hour prior to embryo transfer. Serum progesterone concentrations was measured by an electrochemiluminescence immunoassay (Cobas® Elecsys Progesterone III, Roche diagnostics GmbH, Germany). The intra-assay coefficient of variation was 2.4% and the inter-assay coefficient of variation was 3.9%. The sensitivity of the assay was 0.03 μg/l.

Preimplantation genetic test for aneuploidy (PGT-A)
The NGS platform (Reproseq PGS Kit, Life-Thermofisher, USA) used in this study was previously validated and published elsewhere [14, 15]. Embryos were diagnosed as euploid, aneuploid or chaotic abnormal.

Pregnancy outcome measurements
A human chorionic gonadotrophin (β-hCG) test was performed 12 days after embryo transfer. The test was considered positive if the β-hCG level was > 5 IU/l. Clinical pregnancy was defined as detection of an intrauterine gestational sac by TV-USG, and ongoing pregnancy was defined as a viable pregnancy detected by ultrasound examination at 16 weeks of gestation. Miscarriage was defined as loss of clinical pregnancy before gestational week 12.

Data collection and analyses
The records of 168 patients from the same IVF center were examined to determine the cycle outcome. Thus, the clinical pregnancy, ongoing pregnancy and miscarriage rates were investigated. All statistical analyses were performed with the SPSS for Windows software package version 25 (SPSS, Chicago, USA). A p-value of ≤ 0.05 was considered to indicate statistical significance for all statistical tests.

First, the distributions of continuous parameters were evaluated using the Kolmogorov-Smirnov test to determine whether each variable followed a normal distribution. One hundred sixty-eight patients were then divided into two groups according to the presence or absence of ongoing pregnancy. Because the continuous variables did not follow a normal distribution, they were reported as median (minimum-maximum) values, and a non-parametric independent median test was used to compare the values of the two groups.

To identify the approximate range of the statistically significant difference, the range of serum P levels on the day of ET was narrowed by examining quartiles; the 25th, 50th, and 75th percentiles (Q1, Q2, Q3 and Q4). Q1 included 0–25%, Q2 included 25–50%, Q3 included 50–75% and Q4 included 75–100%. Then, all possible
two-way companions are performed between the quartile groups.

All categorical variables were compared among groups with a Chi-square test. To determine which factors affected the outcome of an ongoing pregnancy, a binary logistic regression analysis was performed with a forward stepwise conditional procedure. The variables included in the binary logistic regression model were female age, body mass index, sperm concentration, number of previous miscarriages, number of live birth, number of oocytes retrieved, fertilization rate, E$_2$ levels on P administration day, P levels on P administration day, endometrium thickness and serum P levels on the day of ET. Only statistically significant factors were included in the final model and are reported in Table 3.

**Results**

A total of 168 cycles of euploid blastocysts used for FET were evaluated. The β-hCG-positive rate, clinical pregnancy rate, OPR and miscarriage rate were 69.6% (117/168), 64.3% (108/168), 58.9% (99/168) and 8.3% (9/108), respectively. Data were then categorized according to the presence (Group I; $n = 99$) or absence (Group II; $n = 69$) of an ongoing pregnancy. Female age, BMI, sperm concentration, number of oocytes retrieved, number of miscarriages, number of previous live birth, number of mature oocytes (MII), the rate of fertilized oocytes with two pronuclei (2PN), and FET parameters such as endometrial thickness, E$_2$ and P levels on the day of P administration were found to be similar between the groups. P levels on the day of the day of ET (ng/ml) were significantly higher in Group I (28 (5.6–76.4) vs 16.4 (7.4–60) $p = 0.039$) (Table 1). There was no difference in ICM and trophoectoderm scores between the two groups.

The mean serum P level on the day of ET was 33.2 ± 23 ng/ml. Serum P values were divided into quartiles (Q). The serum P range for each quartile were Q1: < 13.6 ng/ml ($n = 42$), Q2: 13.6–24.3 ng/ml ($n = 43$), Q3: 24.4–53.2 ng/ml ($n = 42$), and Q4: > 53.2 ng/ml ($n = 41$).

Table 2 shows the clinical outcome of patients in Q1, Q2, Q3 and Q4. Female age (33 (26–43), 32 (27–44), 34 (23–42) and 31 (28–44) respectively $p = 0.86$) and BMI (25.1 (20.7–29.6), 25.1 (17.9–32.8), 23.3 (18.4–33.5) and 22.3 (18.4–26.4) respectively $p = 0.211$) were similar among the 4 groups. Clinical pregnancy rates (15/42 (35.7%), 34/43 (79.1%), 25/42 (59.5%) and 34/41 (82.9) respectively, $p < 0.001$) and OPR (11/42 (26.2%), 32/43 (74.4%), 22/42 (52.4%) and 34/41 (82.9%) respectively, $p < 0.001$)

| Table 1 Characteristics of patients grouped according to the presence of ongoing pregnancy |
|------------------------------------------------------------------------------------------|
| **Variable** | **Ongoing pregnancy ($n = 99$)** | **Non-ongoing pregnancy ($n = 69$)** | **p-value** |
| Female age (years) | 33 (23–44) | 33 (26–42) | 0.555 |
| BMI (kg/m$^2$) | 23.9 (17.9–33.2) | 24.6 (18.4–33.5) | 0.683 |
| Sperm concentration (million sperm/ml) | 22 (0.4–75) | 20 (0.1–60) | 0.911 |
| No. of oocytes retrieved | 10 (3–35) | 11 (1–40) | 0.896 |
| No. of MII oocytes | 8 (2–28) | 10 (1–33) | 0.282 |
| Fertilization rate (%) | 87.5 (45.45–100) | 83.3 (57.14–100) | 0.318 |
| E$_2$ levels on P administration day (pg/ml) | 260 (115–551) | 286 (119–2018) | 0.295 |
| P levels on P administration day (ng/ml) | 0.08 (0.05–0.90) | 0.05 (0.01–0.86) | 0.332 |
| Endometrial thickness (mm) | 9 (7–12.3) | 9.1 (7.5–14) | 0.494 |
| P levels on the day of ET (ng/ml) | 28 (5.6–76.4) | 16.4 (7.4–60) | 0.039* |
| No. of miscarriages | 0 (0–4) | 0 (0–5) | 0.945 |
| No. of previous live births | 0 (0–1) | 0 (0–1) | 0.337 |
| Trophoectoderm Score | | | |
| A (%/n) | 14.1 (14) | 24.6 (17) | 0.209 |
| B (%/n) | 34.3 (34) | 27.5 (19) | 0.642 |
| C (%/n) | 51.5 (51) | 47.8 (33) | 0.642 |
| ICM Score | | | |
| A (%/n) | 27.3 (27) | 31.9 (22) | 0.642 |
| B (%/n) | 63.6 (63) | 56.5 (39) | 0.642 |
| C (%/n) | 9.1 (9) | 11.6 (8) | 0.642 |

*statistically significant difference; $p < 0.05$

Values are given as the median (minimum-maximum) or number (percentage)

BMI, M2, 2PN, E$_2$, and P denote body mass index, mature oocyte, 2 pronuclei, oestradiol, and progesterone, respectively.

$p$-values were calculated with a Chi-square test and a non-parametric independent samples median test.
**Table 2** Clinical outcome according to serum P values (ng/ml) on the day of ET

| Variable                  | Q1 (< 13.6 ng/ml) (n = 42) | Q2 (13.6–24.3 ng/ml) (n = 43) | Q3 (24.4–53.2 ng/ml) (n = 42) | Q4 (> 53.2 ng/ml) (n = 41) | p-value
|---------------------------|-----------------------------|--------------------------------|-----------------------------|-----------------------------|--------
| Female age (years)        | 33 (26–43)                  | 32 (27–44)                     | 34.5 (23–42)                | 31 (28–44)                  | 0.86   |
| BMI (kg/m²)               | 25.1 (20.7–29.6)            | 25.1 (17.9–32.8)               | 23.3 (18.4–33.5)            | 22.3 (18.4–26.4)            | 0.211  |
| Clinical Pregnancy rate n (%) | 15/42 (35.7)               | 34/43 (79.1)                   | 25/42 (59.5)                | 34/41 (82.9)                | < 0.001*|
| Ongoing Pregnancy rate n (%) | 23/42 (74.4)               | 22/42 (52.4)                   | 34/41 (82.9)                | < 0.001*                    |        |
| Miscarriage rate n (%)    | 4/15 (26.7)                 | 2/34 (5.9)                     | 3/25 (12)                   | 0/34 (0)                    | 0.015* |

*p < 0.001) were found to be significantly lower in Q1 group. Miscarriage rates (4/15 (26.7%), 2/34 (5.9%), 3/25 (12%) and 0/34 (0%) respectively, p = 0.015) were found to be higher in Q1 group.

When all of the parameters were assessed with binary logistic regression analysis to identify which covariates and factors effect the ongoing pregnancy outcomes, the serum P level on the day of ET (p < 0.001, OR: 1.033, 95% CI: 1.009–1.056) was the only significant variable (Table 3). The serum P levels on the day of ET was found to have a weak negative correlation with BMI (rho: −0.284; p = 0.001) and had a positive correlation with the serum P levels on the day of P administration (rho: 0.224; p = 0.001) (Additional file 1: Table S1).

The ROC curve showed a significant predictive value of the serum P level on the day of ET for the OPR, with an AUC (95%CI) of 0.716 (0.637–0.795). The optimal serum P threshold for which the sensitivity and specificity for the OPR was 20.6 ng/ml (71.7% sensitivity, 56.5% specificity) (Fig. 2). The OPR around this threshold was 41.8%(28/67) versus 70.3%(71/101) for serum P ≤ 20.6 ng/ml, respectively (p < 0.001). Miscarriage rates were 15.2% (5/33) versus 5.3% (4/41), respectively (p = 0.089).

**Discussion**

In this prospective study, one of the inclusion criteria was the use of a single euploid, blastocyst biopsied on day 5 for FET. This approach enhanced the elimination of confounders such as female age, embryo quality, and COH protocols. The results of this study demonstrated that the P level on the day of ET utilizing a single euploid blastocyst was an independent prognostic factor for an ongoing pregnancy. Patients with serum P levels < 13.6 ng/ml prior to FET and who underwent endometrial preparation via HRT using IM administration of P had a significantly lower likelihood of an ongoing pregnancy. The ROC curve showed a statistically significant value, but the optimal threshold revealed modest specificity and sensitivity.

A receptive endometrium for the implantation of embryos can be achieved by exogenous administration of oestriodiol and P. The serum P concentrations achieved are higher with IM administration than with vaginal administration, whereas endometrial tissue P concentrations are higher after vaginal administration [16]. Regarding our clinical experience most patients opt for the vaginal route due to the self-administration advantage, ease of use, and reduced pain. However, in a recent, randomized, three-armed study, administration of 50 mg daily of IM P alone, twice daily vaginal administration of 200 mg P, and twice daily vaginal administration of 200 mg P plus IM administration of 50 mg P every 3rd day were compared in vitrified-warmed blastocyst transfers. The results showed that only the vaginal P arm had a significantly reduced pregnancy outcome [17].

Some factors may be able to alter P levels after vaginal administration, such as sexual intercourse, poor patient compliance and differences in vaginal absorption, distribution, and metabolism [18]. Low P levels were reported in more than one-third of patients who underwent daily vaginal administration of 600 mg micronized progesterone in a retrospective study [6]. Although increasing the vaginal P dose to 1200 mg increased the serum P levels in most cases, it was still insufficient to improve the clinical outcome. These variations were also observed for IM administration [10, 11]. In our study, the serum P levels on the day of ET exhibited a wide range. Although serum P levels on the day of ET were negatively correlated with BMI (rho: −0.284 p = 0.001), this weak correlation is not sufficient to explain wide range of values. Personal metabolic variations should also be considered as a related mechanism. Inter-individual variations in serum P levels make it difficult to predict P levels.
values without monitoring the luteal phase. In addition, monthly or daily variations and their effect on clinical outcomes should also be evaluated.

Data regarding the optimal range of P values on the day of ET in cycles utilizing IM P administration are limited and conflicting [10, 11]. In 2014, Brady et al. evaluated the association between serum P levels on the day of ET and pregnancy rates in fresh donor IVF/ICSI cycles among day 3 transfers. They reported that serum P levels on the day of ET in fresh donor IVF/ICSI cycles were positively correlated with clinical pregnancy and live birth rates. The IM P dosage was not standard (50 or 100 mg/day) [10]. Additionally, regarding recipient P levels measured at ET, the P dose was increased by 50–100% if the level was < 20 ng/ml after ET. However, this was insufficient to rescue the pregnancy rates. Similar to our study, BMI was found to be related to P levels. Moreover, the study included donor cycles performed on patients with 1, 2 or 3 embryos transferred on day 3. The number and quality of embryos transferred were not reported in the comparison groups, which might cause a bias. In contrast to this study, Kofinas et al. retrospectively analyzed 213 single euploid ETs, and P levels > 20 ng/ml on the day of ET with a single euploid embryo were found to be associated with a decreased OPR and live birth rate [11]. In our study, the mean serum P value was 33.2 ng/ml, and almost 40% of the patients had a serum P value lower than 20 ng/ml. Kofinas et al. did not report the percentage or number of patients who had P levels > 20 ng/ml. However, the timing of P administration was changed two days later from morning to evening, which might affect the P values.

**Fig. 2** Receiver operating characteristic (ROC) curve for prediction of the OPR using serum P levels on the day of ET. AUC = area under the curve.

AUC (95% CI) = 0.716 (0.637-0.795)

Sensitivity: 71.7%

Specificity: 56.5%

P Level: 20.6 ng/ml
The ET and serum sampling times were not stated. BMI was also not reported in the study, which could be an independent factor for the live birth rate and miscarriage rate after euploid embryo transfer [19]. In our study, BMI was found to be similar in the groups with and without ongoing pregnancy. Serum P levels on the day of ET were related to BMI, and after adjusting the variables, the only significant factor that could affect the OPR was the P levels on the day of ET. Although, the correlation between the BMI and serum P levels on the day of ET was weak, women with a higher BMI would likely benefit from higher doses of P from the start of administration. In the obese women, the thick subcutaneous tissue may negatively affect the optimal penetration of the lipophilic progesterone into the muscle, or their serum P levels may be lower due to a larger volume of distribution [10]. Further pharmacokinetic research is needed to define optimal dosing for these patients, to obtain serum P levels ≥13.6 ng/ml. However, according to the results of studies involving vaginal administration of P, increasing the dose does not proportionally increase the systemic and tissue P concentrations [18].

The effects of serum P concentrations on the development of endometrial histology and gene expression patterns were reported in a case–control experimental trial, including 46 healthy young females. Morphological delay was observed in the group supplemented with lower P concentrations. Higher P levels resulted in normal histology but aberrant gene expression [20]. This experimental trial supports the clinical study of Yovich et al., which reported that the likelihood of pregnancy in cryopreserved embryo transfer cycles under hormonal control is highly dependent on the circulating concentration of P, with an optimal P concentration of 70–99 nmol/l after vaginal administration [9]. Moreover, in animal studies, both low and high P concentrations were negatively associated with implantation [21]. Evidence based on one prospective and 4 retrospective studies using vaginal administration supports the negative impact of low serum P levels on pregnancy outcome, although the data do not support the previous finding that higher P levels have a detrimental effect, which is similar to the result of our study [5–8]. Future studies are warranted to analyze and monitor serum P values in standard luteal phase support.

P is essential for the implantation and maintenance of pregnancy; therefore any reduction in P levels or P resistance will likely be associated with changes in gene expression in the endometrium. Abnormal B-cell CLL/lymphoma 6 (BCL6) expression in the endometrium of infertile women was found to be associated with endometrial P resistance [22]. High BCL6 expression is a biomarker for endometrial inflammation and is associated with inflammatory proteins. In addition, oestriol and P are important components of immune reactions during implantation and pregnancy [23]. It could be speculated that the inflammatory pathway is regulated by certain serum and tissue P levels, and appropriate tissue activity of P should be achieved to allow for an adequate immunological environment to increase the likelihood of implantation and reduce pregnancy loss. Individualization of not only the dosage and but also the tissue activity of P may have a positive impact on the pregnancy outcome.

In artificial cycles, endometrial preparation is sustained both with vaginal and IM P administration. After the first dose, P levels increase rapidly in circulation and reach a steady state after 24 h, which makes monitoring of the luteal phase important [16]. A previous historical study showed that very low P levels are sufficient to induce histological endometrial maturation, but endometrial histological maturation is not a valid measure of the quality of luteal function or endometrial receptivity [24]. This result is supported by a clinical trial which showed that increasing the vaginal P administration dosage in FET cycles increased live birth rates and decreased abortion rates [25]. Additional studies are warranted to address the optimal route, dosage, and exposure time of P to individualize the luteal phase support in FET cycles.

The main limitation of the study is that only women with appropriate endometrial thickness and good quality euploid blastocysts were included. Extrapolation to different populations or to other doses of P via IM administration will require further validation. The study may have been underpowered to detect small differences.

**Conclusions**

In conclusion, the results of our study showed that the P level on the day of ET is an independent prognostic factor for an ongoing pregnancy. The effectiveness of hormonal monitoring immediately before FET has not been proven to be beneficial. However, determining the threshold levels as well as the dose for the individualization of P treatment may improve the pregnancy outcome.

**Supplementary information**

**Supplementary information** accompanies this paper at https://doi.org/10.1186/s12958-019-0549-9.

**Additional file 1: Table S1.** Relationship between serum P level on the day of ET and the basic and FET cycle characteristics of patients

**Abbreviations**

AH: Assisted Hatching; AUC: Area Under The Curve; BCL6: B-cell CLL/lymphoma 6; COH: Controlled Ovarian Hyperstimulation; E2: Oestrodiol; ET: Elective Single Embryo Transfer; FET: Frozen-Warmed Embryo Transfer; HRT: Hormone Replacement Therapy; IM: Intramuscular; NGS: Next Generation Sequencing; P: Progesterone; PGT-A: Preimplantation Genetic
Screening for Aneuploidy; PN: Pronuclei; TV-USG: Transvaginal Ultrasoundography; β-hCG: Human Chorionic Gonadotrophin

Acknowledgements
The authors declare no conflict of interest.

Authors’ contributions
Fazilet Kubra Boynukalin: Substantial contributions to design, acquisition, analysis and interpretation of data, drafting the article, critical revision of manuscript and approval of final version of the manuscript. Meral Gulтомрук: Substantial contributions to conception and design of project, analysis of data, critical revision of manuscript and approval of final version of the manuscript. Emre Turgut: Substantial contributions to analysis of data, critical revision of manuscript and approval of final version of the manuscript. Berfu Demir: Substantial contributions to analysis of data, critical revision of manuscript and approval of final version of the manuscript. Necati Findikli: Substantial contributions to analysis of data, critical revision of manuscript and approval of final version of the manuscript. Onurer Serdarogullari: Substantial contributions to analysis of data, critical revision of manuscript and approval of final version of the manuscript. Zalile Yarinken: Data analysis critical, revision of manuscript and approval of final version of the manuscript. Mustafa Bahcecci: Substantial contributions to conception and design of project, critical revision of manuscript and approval of final version of the manuscript.

Funding
No funding.

Availability of data and materials
Available only on request.

Ethics approval and consent to participate
Consent obtained from all the others.

Consent for publication
Consent obtained from all the others.

Competing interests
Nothing to declare.

Author details
1 Bahcecci Health Group, Hakki Yeten Cad. No: 11 Terrace Fulya, Fulya, Istanbul, Turkey. 2 Department of Statistics, Cyprus Science University, 99320 Dr. Fazl Kucuk Cad. Oznakcy, Kyrenia, Cyprus.

Received: 29 June 2019 Accepted: 25 November 2019

Published online: 29 November 2019

References
1. Ghobara T, Gelbaya TA, Ayeleke RO. Cycle regimens for frozen-thawed embryo transfer. Cochrane Database Syst Rev. 2017;7:CD003414.
2. Mackens S, Santos-Ribeiro S, Van de Vijver A, Raccia A, Van Lansdyt L, Tournaye H, et al. Frozen embryo transfer: a review on the optimal endometrial preparation and timing. Hum Reprod. 2017;32(11):2234–42.
3. Yarali H, Polat M, Mumusoglu S, Yarali I, Bozdag G. Preparation of endometrium for frozen embryo replacement cycles: a systematic review and meta-analysis. J Assist Reprod Genet. 2016;33(10):1287–304.
4. Groenewoud ER, Cohen BJ, Macklon NS. Programming the endometrium for deferred transfer of cryopreserved embryos: hormone replacement versus modified natural cycles. Fertil Steril. 2018;109(5):768–75.
5. Alsbjerg B, Thomsen L, Elbaek HO, Laursen R, Povlsen BB, Haahr T, et al. Progesterone levels on pregnancy test day after hormone replacement therapy-cryopreserved embryo transfer cycles and related reproductive outcomes. Reprod Biol Med Online. 2018;37(4):641–7.
6. Cedrin-Durnerin I, Insand T, Mahdjoub S, Soncog C, Seroka A, Comtet M, et al. Serum progesterone concentration and live birth rate in frozen-thawed embryo transfers with hormonally prepared endometrium. Reprod Biol Med Online. 2019;58(3):472–80.
7. Gaggiotti-Marre S, Martinez F, Coll I, Garcia S, Alvarez M, Parriego M, et al. Low serum progesterone the day prior to frozen embryo transfer of euploid embryos is associated with significant reduction in live birth rates. Gynecol Endocrinol. 2019;35(4):399–42.
8. Labarta E, Mariani G, Holtmann N, Celada P, Remohi J, Bosch E. Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod. 2017;32(12):2437–42.
9. Yovich JL, Concejao JL, Stanger JD, Hinchcliffe PM, Keane KN. Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement. Reprod Biol Med Online. 2015;32(3):190–91.
10. Bracy PC, Kaser DJ, Ginsburg ES, Ashby RK, Missmer SA, Correia HF, et al. Serum progesterone concentration on day of embryo transfer in donor oocyte cycles. J Assist Reprod Genet. 2014;31(5):569–75.
11. Koffnas JD, Blakemore J, McCulloch DH, Griffo J. Serum progesterone levels greater than 20 ng/dl on day of embryo transfer are associated with lower live birth and higher pregnancy loss rates. J Assist Reprod Genet. 2015;32(9):1393–9.
12. Serdarogullari M, Coban O, Boynukalin FK, Bilgin EM, Findikli N, Bahcecci M. Successful application of a single warming protocol for embryos cryopreserved by either slow freezing or vitrification techniques. Syst Biol Reprod Med. 2019;65(1):12–9.
13. Gardner DK, Schoolcraft WB. Culture and transfer of human blastocysts. Curr Opin Obstet Gynecol. 1999;11(3):307–11.
14. Kung A, Munne S, Bankowski B, Coates A, Wells D. Validation of next-generation sequencing for comprehensive chromosome screening of embryos. Reprod Biol Med Online. 2015;31(6):760–9.
15. Wells D, Kaur K, Griffo J, Glassner M, Taylor JC, Fragoulis E, et al. Clinical utilisation of a rapid low-pass whole genome sequencing technique for the diagnosis of aneuploidy in human embryos prior to implantation. J Med Genet. 2014;51(8):553–62.
16. Paulson RJ, Collins MG, Yanikov VL. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J Clin Endocrinol Metab. 2014;99(1):4241–9.
17. Devine K, Richter KS, Widra EA, Meckelby JL. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018;109(2):266–75.
18. Memniam KS, Leake KA, Elliot M, Matthews ML, Usadi RS, Hurst BS. Sexual absorption of vaginal progesterone: a randomized control trial. Int J Endocrinol. 2015;2015:685281.
19. Tremellen K, Pearce K, Zander-Fox D. Increased miscarriage of euploid embryos in obese women undergoing cryopreserved embryo transfer. Reprod Biol Med Online. 2017;34(1):90–7.
20. Young SL, Savaris RF, Lessey BA, Sharkey AM, Balthazar U, Zaino RJ, et al. Effect of randomized serum progesterone concentration on post-transfer endometrial histologic development and gene expression. Hum Reprod. 2012;27(9):1903–14.
21. Lonergan P, Forde N, Spencer T. Role of progesterone in embryo development in cattle. Reprod Fertil Dev. 2016;28(1):261–66.
22. Almquist LD, Likes CE, Stone B, Brown KR, Savaris R, Forstein DA, et al. Endometrial BC6L testing for the prediction of in vitro fertilization outcomes: a cohort study. Fertil Steril. 2017;108(6):1093–6.
23. La Rocca C, Carbone F, Longobardi S, Matarese G. The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett. 2014;162(1 Pt A):41–8.
24. Usadi RS, Golf M, Lessey BA, Linninger RA, Zaino RJ, Fritz MA, et al. Endometrial development and function in experimentally induced luteal phase deficiency. J Clin Endocrinol Metab. 2008;93(10):4058–64.
25. Alemdarogullari B, Polyzos NP, Elbaek HO, Povlsen BB, Andersen CY, Humaidan P. Increasing vaginal progesterone gel supplementation after frozen-thawed embryo transfer significantly increases the delivery rate. Reprod Biol Med Online. 2013;26(2):133–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.